LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · IEX Real-Time Price · USD
0.490
-0.010 (-2.02%)
At close: Jul 19, 2024, 4:00 PM
0.410
-0.080 (-16.31%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
LakeShore Biopharma Revenue
Revenue in the quarter ending December 31, 2023 was $164.98M. In the fiscal year ending March 31, 2023, LakeShore Biopharma had annual revenue of $687.20M with 36.63% growth.
Revenue (ttm)
$687.20M
Revenue Growth
+36.63%
P/S Ratio
n/a
Revenue / Employee
$889,005
Employees
773
Market Cap
92.26M
Revenue Chart
* The company reports in CNY currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 687.20M | 184.25M | 36.63% |
Mar 31, 2022 | 502.95M | 245.93M | 95.69% |
Mar 31, 2021 | 257.02M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLSB News
- 17 days ago - LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - PRNewsWire
- 2 months ago - YS Biopharma Announces Name Change to LakeShore Biopharma - PRNewsWire
- 2 months ago - YS Biopharma Announces Results of Extraordinary General Meeting - PRNewsWire
- 2 months ago - YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PRNewsWire
- 3 months ago - YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PRNewsWire
- 3 months ago - YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 - PRNewsWire
- 3 months ago - YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine - PRNewsWire
- 3 months ago - YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 - PRNewsWire